Tag

Ai In Drug Discovery

All articles tagged with #ai in drug discovery

technology1 month ago•83 min saved

AI-driven platform enables billion-molecule virtual screens for rapid drug discovery

Nature Biotechnology introduces AdaptiveFlow, an open-source platform that enables AI-guided ultralarge virtual screenings of 69 billion Enamine REAL Space molecules. It uses an 18-dimensional property grid and Adaptive Target-Guided Virtual Screens to efficiently narrow chemical space, with optional active learning to further accelerate prioritization. The suite supports ~1,500 docking protocols, GPU/CPU cloud scaling (demonstrated up to 5.6 million CPUs on AWS), SELFIES and stereoisomer enumeration, and ML-assisted triage to reduce docking calls. Experimental validation yielded nanomolar inhibitors for FSP1 and PARP1 with structural insights, showcasing scalable AI-driven drug discovery.

via Nature|

#adaptiveflow #ai-in-drug-discovery #docking

technology4 months ago•2 min saved

Pfizer Taps Chai Discovery to Fast-Track AI-Designed Biologics

Chai Discovery announced a license with Pfizer to deploy its frontier AI platform, including the Chai-3 model and a Pfizer-custom model, within Pfizer’s drug discovery engine to accelerate biomolecule design and target hard-to-reach areas. Pfizer will gain early access to Chai-3, which advances antibody design and generalization, alongside a tailored model leveraging Pfizer’s data. The deal highlights growing use of AI in pharma to shorten discovery timelines that traditionally span months to weeks.

via Business Wire|

#ai-in-drug-discovery #antibody-design #biopharma

business7 months ago•4 min saved

AI-powered Generate Biomedicines targets record biotech IPO with a $400M raise

Generate Biomedicines is launching an Nasdaq IPO by selling 25 million shares at $16 (potentially up to 3.75 million more shares), targeting about $400 million in proceeds and up to $460 million with the underwriters’ option. The funds will advance Phase 3 asthma trials for its AI-designed GB-0895 and support other programs, as investor interest in biotech IPOs rebounds. The company emphasized its AI-driven drug discovery platform and partnerships with Amgen and Novartis, while aiming for capital efficiency amid a renewed funding environment.

via Fierce Biotech|

#ai-in-drug-discovery #biotech #business

technology9 months ago•19 min saved

NVIDIA and Lilly Launch AI-Driven Lab to Accelerate Drug Discovery

NVIDIA and Eli Lilly unveiled a first-of-its-kind AI co-innovation lab in the San Francisco Bay Area, committing up to $1 billion over five years to fuse Lilly’s biology and medicine expertise with NVIDIA’s AI and accelerated computing, via the BioNeMo platform and Vera Rubin architecture. The initiative will create a continuous learning system that links Lilly’s wet labs with computational dry labs for 24/7 AI-assisted experimentation, develop large biomedical foundation and frontier models, and extend into manufacturing, clinical development, and supply chains using robotics, digital twins, and physical AI. The lab is set to begin in South San Francisco this year, aiming to accelerate drug discovery and scale medicine production through enhanced AI infrastructure and collaboration between the two companies’ experts and ecosystems.

via NVIDIA Newsroom|

#ai-in-drug-discovery #co-innovation-lab #lilly